{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:27:06Z","timestamp":1791019626421,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.ctrv.2009.12.005","type":"journal-article","created":{"date-parts":[[2010,1,16]],"date-time":"2010-01-16T09:16:11Z","timestamp":1263633371000},"page":"195-205","source":"Crossref","is-referenced-by-count":122,"title":["Intravesical therapy for superficial bladder cancer: A systematic review of randomised trials and meta-analyses"],"prefix":"10.1016","volume":"36","author":[{"given":"Mike D.","family":"Shelley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm D.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Kynaston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl.","key":"10.1016\/j.ctrv.2009.12.005_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/03008880802285032","article-title":"The global burden of urinary bladder cancer","volume":"218","author":"Parkin","year":"2008","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.ctrv.2009.12.005_bib2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavity bacillus Calmette\u2013Guerin in the treatment of superficial bladder cancer","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ctrv.2009.12.005_bib3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette\u2013Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ctrv.2009.12.005_bib4","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette\u2013Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.ctrv.2009.12.005_bib5","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0895-4356(99)00203-6","article-title":"Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials","volume":"53","author":"Huncharek","year":"2000","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.ctrv.2009.12.005_bib6","first-page":"27","article-title":"A combined analysis of EORTC\/MRC randomized clinical trials for the prophylactic treatment of TaT1 bladder cancer. Eortc Genito-Urinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on superficial bladder cancer","volume":"64","author":"Pawinski","year":"1996","journal-title":"Acta Urologica Belgica"},{"key":"10.1016\/j.ctrv.2009.12.005_bib7","first-page":"53","article-title":"Meta-analysis of intravesical therapy for superficial bladder cancer: superiority of bacillus Calmette\u2013Guerin may be confined to high risk patients","volume":"85","author":"Shelley","year":"2001","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2009.12.005_bib8","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette\u2013Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"issue":"7","key":"10.1016\/j.ctrv.2009.12.005_bib9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille Calmette\u2013Guerin with a reduced dose of 27mg in superficial bladder cancer","volume":"89","author":"Martinez-Pineiro","year":"2002","journal-title":"BJU Int"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2009.12.005_bib10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1569-9056(03)80754-6","article-title":"Comparison of a standard BCG dose (81mg) versus a three-fold reduced dose (27mg) in high risk superficial bladder cancer (T1G3, Tis). A CUETO prospective randomised study 95012","volume":"2","author":"Martinez-Pineiro","year":"2003","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ctrv.2009.12.005_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1590\/S1677-55382007000100025","article-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette\u2013Guerin (27mg) versus very low-dose bacillus Calmette\u2013Guerin (13.5mg) versus mitomycin C","volume":"34","author":"Bohle","year":"2008","journal-title":"Int Braz J Urol"},{"issue":"3","key":"10.1016\/j.ctrv.2009.12.005_bib12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.1987.5.3.441","article-title":"A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette\u2013Guerin therapy of superficial bladder cancer","volume":"5","author":"Badalament","year":"1987","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2009.12.005_bib13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0022-5347(17)43125-9","article-title":"Single course versus maintenance bacillus Calmette\u2013Guerin therapy for superficial bladder tumors: a prospective, randomized trial","volume":"138","author":"Hudson","year":"1987","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ctrv.2009.12.005_bib14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/1097-0142(19950115)75:2<552::AID-CNCR2820750219>3.0.CO;2-H","article-title":"Bacillus Calmette\u2013Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder: four-year results","volume":"75","author":"Akaza","year":"1995","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2009.12.005_bib15","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette\u2013Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ctrv.2009.12.005_bib16","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0022-5347(05)66333-1","article-title":"Control group and maintenance treatment with bacillus Calmette\u2013Guerin for carcinoma in situ and\/or high grade bladder tumors","volume":"165","author":"Palou","year":"2001","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ctrv.2009.12.005_bib17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11684-008-0049-3","article-title":"A meta-analysis of randomized trials of maintenance bacillus Calmette\u2013Guerin instillation efficacy against recurrence of T1G3 bladder tumor","volume":"2","author":"Pan","year":"2008","journal-title":"Front Med China"},{"key":"10.1016\/j.ctrv.2009.12.005_bib18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance bacillus Calmette\u2013Guerin for TaT1 bladder tumours is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"van der Meijden","year":"2003","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ctrv.2009.12.005_bib19","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0022-5347(17)38439-2","article-title":"Prospective randomized comparison of intravesical with percutaneous bacillus Calmette\u2013Guerin versus intravesical bacillus Calmette\u2013Guerin in superficial bladder cancer","volume":"145","author":"Lamm","year":"1991","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ctrv.2009.12.005_bib20","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0022-5347(01)66427-9","article-title":"Intravesical versus intravesical plus intradermal bacillus Calmette\u2013Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors","volume":"155","author":"Luftenegger","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2009.12.005_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000471653","article-title":"Intravesical chemotherapy (Mitomycin C) versus immunotherapy (bacillus Calmette\u2013Gu\u00e9rin) in superficial bladder cancer","volume":"20","author":"Rintala","year":"1991","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ctrv.2009.12.005_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/1078-1439(95)00041-F","article-title":"Randomized intergroup comparison of bacillus Calmette\u2013Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study","volume":"1","author":"Lamm","year":"1995","journal-title":"Urol Oncol: Semin Original Invest"},{"issue":"3","key":"10.1016\/j.ctrv.2009.12.005_bib23","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0022-5347(01)65673-8","article-title":"A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette\u2013Guerin. Participating Clinics","volume":"156","author":"Krege","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2009.12.005_bib24","first-page":"10","article-title":"Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette\u2013Gu\u00e9rin\u2013Tice versus bacillus Calmette\u2013Gu\u00e9rin RIVM in the treatment of patients with pTA\u2013pT1 papillary carcinoma and carcinoma in situ of the urinary bladder","volume":"1","author":"Witjes","year":"1996","journal-title":"Semin Urol Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2009.12.005_bib25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0090-4295(98)00212-X","article-title":"Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette\u2013Guerin\u2013RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group","volume":"52","author":"Witjes","year":"1998","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.ctrv.2009.12.005_bib26","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","article-title":"5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette\u2013Guerin in patients with superficial bladder carcinoma. Swedish\u2013Norwegian Bladder Cancer Study Group","volume":"161","author":"Malmstrom","year":"1999","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ctrv.2009.12.005_bib27","first-page":"167","article-title":"A randomized prospective study of intravesical prophylaxis in non-muscle invasive bladder cancer at intermediate risk of recurrence. Mitomycin chemotherapy vs. BCG immunotherapy","volume":"80","author":"Mangiarotti","year":"2008","journal-title":"Archivio Italiano di Urologia e Andrologia"},{"issue":"5","key":"10.1016\/j.ctrv.2009.12.005_bib28","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","article-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette\u2013Guerin (27mg) versus very low-dose bacillus Calmette\u2013Guerin (13.5mg) versus mitomycin C","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.ctrv.2009.12.005_bib29","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1046\/j.1442-2042.2001.00355.x","article-title":"Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette\u2013Guerin therapy for carcinoma in situ of the bladder","volume":"8","author":"Sekine","year":"2000","journal-title":"Int J Urol"},{"issue":"4","key":"10.1016\/j.ctrv.2009.12.005_bib30","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette\u2013Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2009.12.005_bib31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette\u2013Guerin for non-muscle invasive bladder cancer","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ctrv.2009.12.005_bib32","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","article-title":"Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette\u2013Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma","volume":"52","author":"Friedrich","year":"2007","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ctrv.2009.12.005_bib33","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette\u2013Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"Bohle","year":"2004","journal-title":"Urol"},{"key":"10.1016\/j.ctrv.2009.12.005_bib34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2009.12.005_bib35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette\u2013Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ctrv.2009.12.005_bib36","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0022-5347(01)65936-6","article-title":"Alternating mitomycin C and bacillus Calmette\u2013Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group","volume":"156","author":"Rintala","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2009.12.005_bib37","first-page":"397","article-title":"A prospective and randomised study of recurrence and progression of superficial bladder cancer treated with mitomycin c alone versus alternating mitomycin c and BCG therapy","volume":"46","author":"Gelabert-mas","year":"1993","journal-title":"Archivos Espanoles de Urologia"},{"key":"10.1016\/j.ctrv.2009.12.005_bib38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1569-9056(02)80391-8","article-title":"Alternating mitomycin c, BCG instillations versus BCG alone in the treatment of carcinoma in situ of the urinary bladder. A Nordic study","volume":"1","author":"Kaasinen","year":"2002","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.ctrv.2009.12.005_bib39","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0022-5347(01)62377-2","article-title":"Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette\u2013Guerin versus mitomycin C alone in patients with superficial bladder cancer","volume":"5","author":"Witjes","year":"1998","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ctrv.2009.12.005_bib40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1569-9056(02)80389-X","article-title":"Random trial comparing intravesical chemotherapy with MMC\u2013BCG vs intravesical BCG in patients with intermediate\u2013high risk superficial bladder cancer. Efficacy evaluation of CUETO trial no 93008","volume":"1","author":"Solsona","year":"2002","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ctrv.2009.12.005_bib41","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-5347(05)67446-0","article-title":"Weekly mitomycin C followed by monthly bacillus Calmette\u2013Guerin or alternating monthly interferon-alpha2B and bacillus Calmette\u2013Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma","volume":"164","author":"Kaasinen","year":"2000","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ctrv.2009.12.005_bib42","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/0090-4295(87)90429-8","article-title":"Superficial bladder cancer treated by intravesical bacillus Calmette\u2013Guerin or Adriamycin: multicenter study interim report","volume":"15","author":"Khanna","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.ctrv.2009.12.005_bib43","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette\u2013Gu\u00e9rin for transitional-cell carcinoma of the bladder","volume":"17","author":"Lamm","year":"1991","journal-title":"New Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2009.12.005_bib44","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0022-5347(17)40002-4","article-title":"Bacillus Calmette\u2013Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer","volume":"143","author":"Martinez-Pineiro","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2009.12.005_bib45","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.urology.2005.09.045","article-title":"Sustained prophylactic effect of intravesical bacille Calmette\u2013Gu\u00e9rin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study","volume":"3","author":"Hinotsu","year":"2006","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.ctrv.2009.12.005_bib46","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1442-2042.2005.01064.x","article-title":"Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette\u2013Guerin and epirubicin as adjuvant therapy in superficial bladder cancer","volume":"12","author":"Cheng","year":"2005","journal-title":"Int J Urol"},{"issue":"3","key":"10.1016\/j.ctrv.2009.12.005_bib47","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.ju.0000150425.09317.67","article-title":"Bacillus Calmette\u2013Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906)","volume":"174","author":"de Reijke","year":"2005","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ctrv.2009.12.005_bib48","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0022-5347(05)68555-2","article-title":"Sequential bacillus Calmette\u2013Guerin and epirubicin versus bacillus Calmette\u2013Guerin alone for superficial bladder tumors: a randomized prospective study","volume":"162","author":"Ali-El-Dein","year":"1999","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ctrv.2009.12.005_bib49","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0022-5347(05)65966-6","article-title":"Intravesical instillation of epirubicin, bacillus Calmette\u2013Guerin and bacillus Calmette\u2013Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"166","author":"van der Meijden","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2009.12.005_bib50","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1442-2042.2000.00176.x","article-title":"Clinical experience with BCG alone versus BCG plus epirubicin","volume":"7","author":"Bilen","year":"2000","journal-title":"Int J Urol"},{"key":"10.1016\/j.ctrv.2009.12.005_bib51","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0022-5347(17)52736-6","article-title":"Experience with bacillus Calmette\u2013Guerin in patients with superficial bladder cancer","volume":"128","author":"Brosman","year":"1992","journal-title":"J Urol"},{"issue":"Suppl. 3","key":"10.1016\/j.ctrv.2009.12.005_bib52","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1569-9056(05)80872-3","article-title":"Prophylactic ofloxacine to improve tolerance of BCG intravesical instillations: a randomised prospective, double-blind, placebo-controlled, multicentre study in patients with mid to high risk superficial bladder tumours","volume":"4","author":"Rischmann","year":"2005","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ctrv.2009.12.005_bib53","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1159\/000020051","article-title":"Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group","volume":"36","author":"Witjes","year":"1999","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ctrv.2009.12.005_bib54","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0090-4295(97)00303-8","article-title":"Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette\u2013Guerin and interferon-alpha","volume":"50","author":"Jimenez-Cruz","year":"1997","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.ctrv.2009.12.005_bib55","first-page":"118","article-title":"Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH. A prospective randomized study","volume":"30","author":"Kalble","year":"1991","journal-title":"Urologe"},{"key":"10.1016\/j.ctrv.2009.12.005_bib56","unstructured":"Bercovich E, Deriu M, Manferrari F, Irianni G. BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder. Archivio Italiano di Urologia, Andrologia 1995;67(4):257\u201360."},{"issue":"5","key":"10.1016\/j.ctrv.2009.12.005_bib57","first-page":"538","article-title":"Postoperative intravesical pirarubicin plus bacillus Calmette\u2013Guerin with or without interleukin 2 instillation therapy for superficial bladder cancer","volume":"58","author":"Ao","year":"1996","journal-title":"Nishinihon J Urol"},{"key":"10.1016\/j.ctrv.2009.12.005_bib58","first-page":"203","article-title":"Mitomycin C 30mg for 12 months versus mitomycin C 40mg for 6 months in the prophylaxis of superficial bladder carcinoma G1\u20132","volume":"48","author":"Scaldazza","year":"1996","journal-title":"Minerva Urol Nephrol"},{"issue":"4","key":"10.1016\/j.ctrv.2009.12.005_bib59","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0022-5347(01)66226-8","article-title":"The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up","volume":"155","author":"Tolley","year":"1996","journal-title":"J Urol"},{"issue":"Suppl. 2","key":"10.1016\/j.ctrv.2009.12.005_bib60","first-page":"31","article-title":"A prospective, randomised, multicenter, phase III clinical trial of the effect of different initial therapy regimes and maintenance prophylaxis in superficial bladder cancer, using mitomycin C","volume":"80","author":"Newling","year":"1997","journal-title":"Br J Urol"},{"issue":"2","key":"10.1016\/j.ctrv.2009.12.005_bib61","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000474441","article-title":"Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy?","volume":"31","author":"Schwaibold","year":"1997","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ctrv.2009.12.005_bib62","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S0022-5347(17)42052-0","article-title":"Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study","volume":"140","author":"Heney","year":"1988","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.ctrv.2009.12.005_bib63","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1046\/j.1464-410X.2002.02734.x","article-title":"A randomized comparative dose-ranging study of interferon and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder","volume":"89","author":"Malmstrom","year":"2002","journal-title":"BJU Int"},{"issue":"8","key":"10.1016\/j.ctrv.2009.12.005_bib64","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.5980\/jpnjurol1989.83.1314","article-title":"Prophylactic intravesical instillation therapy in patients with superficial bladder cancer. Results of a randomized prospective study","volume":"83","author":"Tsushima","year":"1992","journal-title":"Jpn J Urol"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2009.12.005_bib65","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/BF00686935","article-title":"Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin","volume":"30","author":"Akaza","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2009.12.005_bib66","doi-asserted-by":"crossref","unstructured":"Faiola V, Montella L, Addeo R, et al. Intravesical gemicitabine versus mitomycin for recurrent superficial bladder tumour (stages pTA and pT1): a randomised prospective study. Eur J Cancer 2008;Suppl. 6:123\u201326.","DOI":"10.1016\/j.ejcsup.2008.06.049"},{"issue":"8","key":"10.1016\/j.ctrv.2009.12.005_bib67","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"10.1016\/j.ctrv.2009.12.005_bib68","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2003.01.089","article-title":"Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma","volume":"21","author":"Colombo","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2009.12.005_bib69","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Di Stasi","year":"2003","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ctrv.2009.12.005_bib70","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0022-5347(17)36198-0","article-title":"A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder","volume":"149","author":"Oosterlinck","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2009.12.005_bib71","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.eururo.2009.01.006","article-title":"Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study","volume":"55","author":"Gudjonsson","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2009.12.005_bib72","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.eururo.2009.06.010","article-title":"Single postoperative instillation of gemcitabine in patients with non-muscle invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo controlled, phase III multicentre study","volume":"56","author":"Bohle","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2009.12.005_bib73","doi-asserted-by":"crossref","unstructured":"Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171(6 Pt 1):2186\u201390.","DOI":"10.1097\/01.ju.0000125486.92260.b2"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573720900187X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573720900187X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T05:36:46Z","timestamp":1558762606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573720900187X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S030573720900187X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2009.12.005","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}